Phase 1 N=12 Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors
Head and Neck Cancer
Primary: Number of Participants With Side Effects After Ad/PNP-F-araAMP Treatment — 12; 8; 8; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 Effects of Salsalate on Prandial-Induced Vascular Inflammation After Spinal Cord Injury (SCI)
Spinal Cord Injury
Primary: Change in Area Under the Curve (AUC) for Lipemia (Triglycerides) at Visits 2-3 or 4-5 Depending on Order of Treatment Assignment. — -34; -62 mg*min/dL
Phase 4 N=56 Effect of Raltegravir on Endothelial Function in HIV-Infected Patients
HIV Infection · Inflammation · Cardiovascular Disease
Primary: Endothelial Function Measured by Brachial Artery Flow-mediated Dilation(FMD) — 3.4; 2.9 millimeters
Phase 2 N=45 Comparison of Intratechal Levobupivacaine and Adding With Sufetanil and Fentanyl in Ceserean Section
Anesthesia
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 5; 10; 9 participants
Phase 3 N=57 Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
Ankylosing Spondylitis
Primary: the Percentage of Patients Fulfilling the Assessment Study (ASAS) Response Criteria Were Determined — 19 percentage of participants
N/A N=110 Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease
Coronary Artery Disease
Primary: Platelet Reactivity by Vasodilator-stimulated Phosphoprotein (VASP) — 32.1; 32.6 PRI%
N/A N=60 Impact of Ticagrelor Re-load on Pharmacodynamic Profiles
Coronary Artery Disease
Primary: Platelet Reactivity Index (PRI) by Vasodilator-stimulated Phosphoprotein (VASP) — 17.87; 23.4 PRI%
Early Phase 1 N=48 Serum Cartilage Oligomeric Matrix Protein Levels After 12 Weeks of Different Exercises
Osteoarthritis · Articular Cartilage Disorder of Knee · Degenerative Lesion of Articular Cartilage of Knee
Primary: Changes in Serum COMP Accumulation, Triggered by Acute Exercise, After 12 Weeks of Different Regular Exercises — -1.60; -0.53; -0.19; -0.12 U/l
Phase 2 N=160 Preventing Urinary Tract Infection Post-Surgery
Urinary Tract Infection
Primary: Participants With Clinically-diagnosed and Treated UTI's. — 15; 30 participants
N/A N=375 Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity
Dentin Sensitivity
Primary: Percentage of Subjects With Reduction From Baseline by at Least 30% in Mean Cold Air VAS Stimulus Score at Week 4 — 44.6; 69.3 percentage of participants — p=<0.001
Phase 2 N=115 Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic
Infantile Colic
Primary: Absolute Change of the Mean Daily Crying and Fussing Time for Three Consecutive Days While on Treatment Versus Baseline. — 284.57; 273.6; 283.91; 185.8 Minutes
N/A N=206 Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 25.24 Percentage of Participants
N/A N=706 Randomized Translational Study to Examine the Effects of Shared Care in Management of Gestational Diabetes
Gestational Diabetes Mellitus
Primary: The Rate of Macrosomia. — 63; 38 participants
Phase 2 N=11 Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia
Aphasia
Primary: Trained Sentence Probe — 20.4; 58.8; 56.0 percentage of correct sentences
Phase 4 N=132 Renal Safety Evaluation After Dotarem®-Enhanced MRI
Renal Insufficiency
Primary: Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis…